• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    1/31/23 6:02:40 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    SC 13G/A 1 lemg20230124b_sc13ga.htm SCHEDULE 13G/A lemg20230124b_sc13ga.htm

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     


    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO §240.13d-2

    (Amendment No. 16)*

     

     


    LeMaitre Vascular, Inc.

    (Name of Issuer)

     

     


    Common Stock, $0.01 Par Value

    (Title of Class of Securities)

     

     

    525558201

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect

    to the subject class of securities, and for any subsequent amendment containing information which would alter

    the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     

     

    1 

    NAME OF REPORTING PERSON

     

    George W. LeMaitre

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a)  ☐        (b)  ☐ Not applicable

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    5

    SOLE VOTING POWER

     

    2,532,694 shares * 

    SHARES

    BENEFICIALLY

    OWNED BY

    6

    SHARED VOTING POWER

     

    0

    EACH

    REPORTING

    PERSON

    7

    SOLE DISPOSITIVE POWER

     

    2,532,694 shares *

    WITH

    8

    SHARED DISPOSITIVE POWER

     

    0

     9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,532,694 shares

     

    *      Includes 24,181 shares subject to options that are exercisable within 60 days of December 31, 2022 and 16,571 restricted stock units subject to annual vesting conditions.

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ☐

     

    Not Applicable

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    11.5%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    Page 2 of 6

     

     

    Schedule 13G

     

         

    Item 1

    (a).

    Name of Issuer:

       

    LeMaitre Vascular, Inc. (the “Company”)

         

    Item 1

    (b).

    Address of Issuer’s Principal Executive Offices:

       

    63 Second Avenue

    Burlington, MA 01803

         

    Item 2

    (a).

    Names of Persons Filing:

       

    George W. LeMaitre

     

    Page 3 of 6

     

     

    Item 2

    (b).

    Address of Principal Business Office or, if None, Residence:

       

    63 Second Avenue

    Burlington, MA 01803

         

    Item 2

    (c).

    Citizenship:

       

    George W. LeMaitre is a citizen of the United States.

         

    Item 2

    (d).

    Title of Class of Securities:

       

    This Schedule 13G report relates to the Common Stock, par value $0.01 per share (the “Common Stock”), of LeMaitre Vascular, Inc.

         

    Item 2

    (e).

    CUSIP Number:

       

    525558201

       

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

       

    Not applicable.

         

    Item 4.

    Ownership.

     
     

    (a)

    Amount Beneficially Owned:

       

    See Item 9 on page 2.

         
     

    (b)

    Percent of Class:

       

    See Item 11 on page 3.

       

    The ownership percentage above is based on an aggregate of 22,086,303 shares of common stock outstanding as of December 31, 2022, according to the Issuer. 

     

    Page 4 of 6

     

     

     

    (c)

    Number of shares as to which the person has:

       

    See Items 5 through 8 on page 2.

         

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     
         

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     
         
    Item 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

      Not Applicable.  
         

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not Applicable.

     
         

    Item 9.

    Notice of Dissolution of Group.

     
     

    Not Applicable.

     
         

    Item 10.

    Certification.

     
     

    Not Applicable.

     

     

    Page 5 of 6

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: January 31, 2023

     

     

    /s/ George W. LeMaitre

     
       

    George W. LeMaitre

     

     

    Page 6 of 6
    Get the next $LMAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

      BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre

      5/5/25 4:39:09 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

      Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

      3/23/21 8:00:00 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    SEC Filings

    See more
    • SEC Form 10-Q filed by LeMaitre Vascular Inc.

      10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/8/25 4:02:12 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/1/25 4:09:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by LeMaitre Vascular Inc.

      DEFA14A - LEMAITRE VASCULAR INC (0001158895) (Filer)

      4/17/25 10:12:37 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Lemaitre George W sold $8,556,631 worth of shares (100,000 units at $85.57) and exercised 34,619 shares at a strike of $44.64, decreasing direct ownership by 3% to 1,827,003 units (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/20/25 7:11:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Director Ross Bridget A sold $312,000 worth of shares (3,750 units at $83.20) and exercised 3,750 shares at a strike of $30.00 (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/14/25 4:03:49 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Shadan Martha

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      3/31/25 5:34:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lemaitre Vascular downgraded by Oppenheimer

      Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

      2/28/25 8:28:09 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Lemaitre Vascular downgraded by Barrington Research

      Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

      2/28/25 7:39:54 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Lemaitre Vascular with a new price target

      Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00

      2/13/25 7:09:15 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LeMaitre Vascular Inc.

      SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

      10/22/24 3:49:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/13/24 5:08:02 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/12/24 3:02:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Financials

    Live finance-specific insights

    See more
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q4 2024 Financial Results

      BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im

      2/27/25 4:05:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care